Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir | Zendy

Kristof Theys | Zendy; J. Snoeck | Zendy; Jurgen Vercauteren | Zendy; Ana Abecasis | Zendy; Anne–Mieke Vandamme | Zendy; Ricardo Camacho | Zendy

Open Access

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir

Author(s) -

Kristof Theys,

J. Snoeck,

Jurgen Vercauteren,

Ana Abecasis,

Anne–Mieke Vandamme,

Ricardo Camacho

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks380

Subject(s) - tenofovir , virology , resistance mutation , population , nucleoside reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , reverse transcriptase , drug resistance , reverse transcriptase inhibitor , hiv drug resistance , medicine , selection (genetic algorithm) , antiretroviral therapy , biology , viral load , genetics , rna , environmental health , artificial intelligence , computer science , gene

The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research